Posters

Surgery vs interferon alpha 2b management for four ocular surface squamous neoplasia

Poster Details

First Author: E. Segovia Maldonado SPAIN

Co Author(s): P. Marti Rodrigo   R. Muñiz Vidal   J. Armentia Perez de Mendiola              

Abstract Details

Purpose:

To describe 4 cases of ocular surface squamous neoplasia (OSSN) and their different management, 2 with interferon alpha 2b and the other 2 with surgical excision

Setting:

Four patients with clinical diagnosis of OSSN, two of them related with a pterygium. All the medical attention was provided at Hospital de l'Esperança (Parc de Salut Mar)

Methods:

Treatment when medical consisted in interferon alfa 2b 4 times a day for a period of 3 and 4 months. Every month clinical response was evaluated as well as tolerance. Surgery was performed with mytomicin and criotherapy, and reconstruction was done with amniotic membrane All the patients had a monthly follow-up the first three months, and every three months on the first year. Pictures were taken whenever necessary Patients reciving surgery were sent to anatomical pathology

Results:

Diagnosis was clinical in patients reciving medical treatment, in the other two cases biopsy confirmed conjunctival intraepithelial neoplasia. All the patients had a complete ophtahlmological exploration before the treatment and a follow up of at least 6 months (range 6-24), so far without recurrence in all four cases

Conclusions:

Both medical and surgical treatment are known effective treatments for OSSN. Patients with surgical treatment can benefit of a biopsy diagnosing severe forms like invasive squamous cell carcinoma, sometimes hard to differentiate from other more benign conditions. Patients reciving medical treatment, when effective can avoid the surgery and its complications. In one of our cases, the extension of the OSSN compromised the limbal stem cell population if surgery were to be chosen In our experience when pterygium is present, surgical treatment is a better option Individualising the treatment for OSSN cases is mandatory.

Financial Disclosure:

None